Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

European, Open-label, Prospective, Multinational, Multicenter Study in Adult Subjects With Type 1 or Type 2 Diabetes Previously on MDI or CSII Therapy. Subjects Home Setting is Considered Routine Practice.

Not Applicable

Completed

Conditions: Type 2 Diabetes, Type 1 Diabetes

Interventions: Device: Accu-Chek® Insight Insulin Pump

First Posted Date: 2014-04-07

Last Posted Date: 2016-09-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 80

Registration Number: NCT02105103

A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: RO4602522
Other: Placebo RO4602522
Other: moxifloxacin placebo
Drug: moxifloxacin

First Posted Date: 2014-04-04

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 203

Registration Number: NCT02104648

A Study Evaluating the Perception of Insertion Pain With Accu-Chek FlexLink and FlexLink Plus Insulin Pump Devices Under Real Life Conditions in Diabetic Patients.

Not Applicable

Completed

Conditions: Diabetes Mellitus Type 2, Diabetes Mellitus Type 1

Interventions: Device: Accu-Chek FlexLink
Device: Accu-Chek FlexLink Plus

First Posted Date: 2014-04-04

Last Posted Date: 2017-04-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 80

Registration Number: NCT02103595

A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: lebrikizumab
Drug: montelukast [Singulair]
Other: placebo

First Posted Date: 2014-04-04

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 313

Registration Number: NCT02104674

Multicenter, Post-marketing, Non-interventional, Observational Study in RA Patients Treated With RoActemra/Actemra (Tocilizumab)

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2014-04-02

Last Posted Date: 2017-12-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 400

Registration Number: NCT02101307

Locations: 🇨🇳
Peking University First Hospital, Beijing, China
🇨🇳
Peking University Third Hospital, Beijing, China
🇨🇳
West China Hospital, Sichuan University, Chengdu, China

and more 22 locations

A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors

Phase 3

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Etrozulimab
Drug: Placebo

First Posted Date: 2014-04-01

Last Posted Date: 2021-08-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 609

Registration Number: NCT02100696

Locations: 🇺🇸
Louisiana Research Center, LLC, Shreveport, Louisiana, United States
🇧🇪
CHU de Liège; Tour de Pathologie, Liège, Belgium
🇺🇸
Gastroenterology Center of the Midsouth, P.C., Memphis, Tennessee, United States

and more 181 locations

A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Lebrikizumab
Drug: Placebo
Drug: Inhaled corticposteroids (ICS)
Drug: Second Asthma Controller Medication

First Posted Date: 2014-03-31

Last Posted Date: 2017-09-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 64

Registration Number: NCT02099656

Locations: 🇺🇸
University of Miami School of Medicine - Sylvester at Deerfield, Deerfield Beach, Florida, United States
🇺🇸
Pen Memory Center, Philadelphia, Pennsylvania, United States
🇬🇧
St Mary's Hospital, London, United Kingdom

and more 25 locations

An Analysis of Treatment Patterns and Outcomes for Basal Cell Carcinoma (BCC) Cancer Participants

Completed

Conditions: Basal Cell Carcinoma

First Posted Date: 2014-03-31

Last Posted Date: 2017-07-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 134

Registration Number: NCT02100111

Locations: 🇮🇹
Irccs Crob, Rionero in Vulture, Basilicata, Italy
🇫🇷
Hôpital St Jacques de Besançon; (Dermatology), Besançon, France
🇫🇷
Hopital Saint Andre CHU De Bordeaux; Dermatologie, Bordeaux, France

and more 39 locations

A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.

Phase 1

Completed

Conditions: Neoplasms, Myelogenous Leukemia, Acute

Interventions: Drug: RO6839921

First Posted Date: 2014-03-28

Last Posted Date: 2018-05-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 68

Registration Number: NCT02098967

Locations: 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇨🇦
University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada
🇺🇸
University of Colorado, Aurora, Colorado, United States

and more 2 locations

A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: methotrexate
Drug: rituximab [MabThera/Rituxan]

First Posted Date: 2014-03-27

Last Posted Date: 2016-11-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 341

Registration Number: NCT02097745

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy